Low immunologic response to highly active antiretroviral therapy in naive vertically human immunodeficiency virus type 1-infected children with severe immunodeficiency

Pediatric Infectious Disease Journal

Volumn 25, Issue 4, 2006, Pages 365-368

  Resino, Salvador ^a   Alvaro Meca, Alejandro ^a   De José, Maria Isabel ^b   Martin Fontelos, Pablo ^b   Gurbindo Gutiérrez, Maria Dolores ^a   Léon, Juan Antonio ^c   Ramos, José Tomás ^d   Ciria, Luis ^e   Muñoz Fernández, Maria Ángeles ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

Author keywords

CD4+; Children; Highly active antiretroviral therapy; Human immunodeficiency virus; Immunosuppression; Naive; Recovery; Viral load

Indexed keywords

ABACAVIR; AMPRENAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; MALE; VIRAL LOAD;

EID: 33645546683     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000207419.50016.5e     Document Type: Article

References (17)

1. Fraaij PL, Verweel G, van Rossum AM, et al. Sustamed viral suppression and immune recovery in HIV type 1-infected children after 4 years of highly active antiretroviral therapy. Clin Infect Dis. 2005;40:604-608.
2. Walker AS, Doerholt K, Sharland M, Gibb DM. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS. 2004:18:1915-1924.
3. van Rossum AM, Scherpbier HJ, van Lochem EG, et al. Therapeutic immune reconstitution in HIV-1-infected children is independent of their age and pretreatment immune status. AIDS. 2001;15:2267-2275.
4. Soh CH, Oleske JM, Brady MT, et al. Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet. 2003;362:2045-2051.
5. + T-cells response to HAART in HIV-infected children: a observational study. Clin Infect Dis. 2003;37:1216-1225.
6. Centers for Disease Control and Prevention. Guidelines for use of antiretroviral agents in pediatric HIV infection. MMWR. 1998:47:1-43.
7. Sharland M, di Zub GC, Ramos JT, Blanche S, Gibb DM. PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection. Pediatric European Network for Treatment of AIDS. HIV Med. 2002:3:215-226.
8. Guidelines for the use antiretroviral agents in pediatric HIV infection. Available at: http://aidsinfo.nih.gov/. Accessed November 30, 2004.
9. Kaufmann GR, Bloch M, Finlayson R, Zaunders J, Smith D, Cooper DA. The extent of HIV-1-related immunodeficiency and age predict the long- term CD4 T lymphocyte response to potent antiretroviral therapy. AIDS. 2002:16:359-367.
10. Tarwater PM, Margolick JB, Jin J, et al. Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27:168-175.
11. van Rossum AM, Geelen SP, Hartwig NG, et al. Results of 2 years of treatment with protease-inhibitor-containing antiretroviral therapy in Dutch children infected with human immunodeficiency virus type 1. Clin Infect Dis. 2002:34:1008-1016.
12. Holmberg SD, Hamburger ME, Moorman AC, Wood KC, Palella FJ Jr. Factors associated with maintenance of long-term plasma human immunodeficiency virus RNA suppression. Clin Infect Dis. 2003:37:702-707.
13. Young B, Kuritzkes DR. Viral kinetics: implications for treatment. AIDS. 1999;13:S11-S17.
14. Haynes BF, Markert ML, Sempowski GD, Patel DD, Hale LP. The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. Annu Rev Immunol. 2000;18:529-560.
15. Spina CA, Prince HE, Richman DD. Preferential replication of HIV-1 in the CD45RO memory cell subset of primary CD4 lymphocytes in vitro. J Clin Invest. 1997;99:1774-1785.
16. Gougeon ML, Lecoeur H, Dulioust A, et al. Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol. 1996:156:3509-3520.
17. Floren LC, Wiznia A, Hayashi S, et al. Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377. Pediatrics. 2003:112: e220-e227.